.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Deloitte
QuintilesIMS
Teva
McKinsey
Citi
Moodys
Merck
Covington
Harvard Business School

About DrugPatentWatch

DrugPatentWatch provides actionable business intelligence on small-molecule drugs

DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.

Use cases for the DrugPatentWatch platform include:

  • Branded pharmaceutical global business intelligence and forecasting
  • Generic drug and API manufacturer portfolio management
  • Wholesalers preventing overstock of off-patent drugs
  • Healthcare payer formulary management and budget management

Different plans are available, focusing on general business intelligence, expired patents, and forecasting.

Revisions and Annual Editions

DrugPatentWatch incorporates data directly from the FDA, Patent and Trademark Office, and other US and foreign government sources. Each is updated as frequently as possible — often daily — providing you with fresh information.

For those seeking information on now-expired patents, annual editions provide historic archives dating back to the Hatch-Waxman Act — arguably for as long as generic drugs have existed.

Database Coverage

DrugPatentWatch contains information on FDA-approved small molecule drugs. For information on biologics see DrugPatentWatch's sister site, BiologicPatentWatch.com

While DrugPatentWatch includes information on expired patents, archived copies of the FDA Orange Book in PDF format are also available in the Orange Book Archives.

Development

DrugPatentWatch is developed by Yali Friedman, Ph.D.

Dr. Friedman is also publisher of the Journal of Commercial Biotechnology and author of Building Biotechnology, which is used as a course text in dozens of biotechnology programs. He also serves as head of data analytics for Scientific American Custom Media, and was also named one of the 100 most influential people in biotechnology by Scientific American.

Dr. Friedman has strong exposure to leading issues in international biotechnology. He is editor of the Scientific American worldVIEW scorecard, a global biotechnology perspective profiling biotechnology industries and innovation capacity in dozens of countries, and has been invited to participate in biotechnology industry development forums for international groups such as APEC, in Europe, and throughout Asia.

Do you have needs beyond DrugPatentWatch's current offerings? Please contact us.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans and Pricing

Clients in 53 Countries

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Fortune- Generics' new legal attack: Big Pharma's aging patents CNN Money - Generics' new legal attack: Big Pharma's aging patents New England Journal of Medicine Barrons

Globalization of Pharmaceutical Drug Innovation The structure and business of biopharmaceutical companies including the management of risks and resources Drug Topics Nature Biotechnology Cardinal Health Business Insider National Bureau of Economic Research

botpot